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E-mail: mdouraghi@tums.ac.irFIG. 1. Venn diagram representing the susceptibility of multidrug-
resistant Acinetobacter baumannii to minocycline (MINO), tetracycline
(TETR), and doxycycline (DOXY).Early studies in the 1970s showed that minocycline was an
effective antibiotic for the treatment of Acinetobacter-associated
infections. At that time, most Acinetobacter baumannii strains
were susceptible to more potent available antibiotics, and
minocycline was not usually chosen for treatment [1–3].
However, the global emergence of multidrug-resistant
A. baumannii (MDR-AB) led to the re-evaluation of old but
safe therapeutic options, such as minocycline [4]. In 2014, the
CLSI re-located minocycline for Acinetobacter species in own
box in test report group B, with breakpoint of 16 mg/L for
susceptibility [5]. In this multicentre study, the in vitro activities
of minocycline and its comparators, tetracycline and doxycy-
cline, against 486 isolates of MDR-AB were assessed. The iso-
lates were collected from ﬁve tertiary or referral hospitals,
including four non-burn centres and one burn centre, located in
the urban area of Tehran, Iran between 2011 and 2013. The
isolates were identiﬁed as A. baumannii with standard micro-
biology tests and blaOXA-51 PCR. MDR-AB isolates were
deﬁned as isolates showing resistance to at least three different
antimicrobial classes, including carbapenems, cephalosporins,
aminoglycosides, or quinolones. The CLSI disk diffusion
breakpoints of 16 mg/L, 15 mg/L and 13 mg/L were
considered to indicate susceptibility to minocycline, tetracy-
cline, and doxycycline, respectively [5].
The mean ± standard deviation of the age of infected patients
was 43 ± 23 years, and 276 (58%) of infected patients wereClinical Microbiology and Infection © 2015 European Society of Cmale. More than half (73%) of isolates recovered from wounds,
71% of isolates recovered from cerebrospinal ﬂuid, 62% of
isolates recovered from blood, 44% of isolates recovered from
respiratory cultures and 25% of isolates recovered from urine
were susceptible to minocycline. MDR-AB isolates had higher
susceptibility to minocycline (56%) than to the comparators
(Fig. 1). Isolates from either burn (76%) or non-burn (46%)
patients showed the highest susceptibility to minocycline, fol-
lowed by doxycycline and tetracycline. The number of
minocycline-susceptible A. baumannii isolates was signiﬁcantly
higher than the number of tetracycline-susceptible isolates
(p<0.05), and was comparable to the number of doxycycline-
susceptible isolates. Among 348 tetracycline-resistant isolates,
160 (45%) were susceptible to minocycline, whereas among
204 doxycycline-resistant isolates, 36 (17%) were susceptible to
minocycline. Only 23 (4%) isolates that were susceptible to
tetracycline were also susceptible to doxycycline and minocy-
cline. The numbers of isolates that were intermediately resis-
tant or resistant to tetracycline but susceptible to doxycycline,
minocycline or both were 253 (52.05%), 190 (39.09%), and 171
(35.1%), respectively.
This study highlights the fact that minocycline remains an
effective therapeutic option, even in a geographical region with a
high rate of MDR-AB. In contrast to the isolates from various
body sites, isolates recovered from the urinary tract showed low
susceptibility to minocycline. The low susceptibility rate com-
bined with the low solubility of minocycline in urine indicate that
minocycline is not the antibiotic of choice for urinary infectionsClin Microbiol Infect 2015; 21: e79–e80
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.07.007
e80 Clinical Microbiology and Infection, Volume 21 Number 11, November 2015 CMI[6]. Although one-sixth of the examined isolateswere susceptible
only to minocycline (and resistant to tetracycline and doxycy-
cline), monotherapy with minocycline should be avoided, owing
to the probability of selection of resistant variants during treat-
ment [7]. Furthermore, cross-resistance or cross-susceptibility
was found in a limited number of isolates, indicating that tetra-
cycline should not be used as a predictive determinant for sus-
ceptibility or resistance to minocycline. Susceptibility to
minocycline should be assessed routinely by the laboratory ac-
cording to CLSI criteria. Moreover, the use of minocycline alone
or in combination needs to be guided by the results of clinical
trials and further laboratory studies.Transparency declarationThe authors declare that they have no conﬂicts of interest.AcknowledgementsThis research was supported by grants from the Academy of
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